CRL vs. SNY: Charles River Laboratories vs. Sanofi Stock Comparison

Company Profile

Charles River Laboratories (CRL) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but CRL is classified in Life Sciences Tools & Services while SNY is classified in Pharmaceuticals.

Charles River Laboratories (CRL) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Charles River Laboratories (CRL) has an aggressive beta of 1.33, indicating higher sensitivity to broad-market moves, while Sanofi (SNY) is defensive at 0.28 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Charles River Laboratories (CRL) at 1.27% and Sanofi (SNY) at 5.72% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

Sanofi (SNY) at 8.20% retains a top-quartile share of revenue as profit, ahead of Charles River Laboratories (CRL) at 1.01%, which keeps about the industry-typical share.

Both Charles River Laboratories (CRL) at 23.42% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Sanofi (SNY) at 5.49% is around its peer norm for revenue growth, while Charles River Laboratories (CRL) at -0.85% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Sanofi (SNY) at 39.43% is around its peer norm for EPS growth, while Charles River Laboratories (CRL) at -1,555.00% falls below its industry range, a notably weak earnings reading.

Growth Metrics

Financial Strength

Both Charles River Laboratories (CRL) at 1.41 and Sanofi (SNY) at 1.12 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Sanofi (SNY) at 0.27 carries an industry-typical debt-to-equity mix, while Charles River Laboratories (CRL) at 0.87 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither Charles River Laboratories (CRL) nor Sanofi (SNY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings; Charles River Laboratories (CRL) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Sanofi (SNY) at 23.40 is near its industry’s usual P/E ratio, while Charles River Laboratories (CRL) at 366.87 sits above its peer range — an unusually expensive price for CRL’s trailing earnings.

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Charles River Laboratories (CRL) at 4.07 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.

Sanofi (SNY) at 1.38 sits in the lower P/B ratio quartile against book while Charles River Laboratories (CRL) at 5.01 is valued near its industry’s middle — SNY is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics